NEW YORK, NY--(Marketwire - April 29, 2011) -
| Highlighted Links |
MacReport Media Publishing |
bHIP Global, a growth-oriented international network marketing and distribution company based in Texas, recently acquired key assets of Ceregenex, Inc., an important Optigenex manufacturing, sales and distribution partner, as part of the company's plan to accelerate its expansion into North America and worldwide markets. In conjunction with the acquisition, bHIP Global and Optigenex have now entered into a long term agreement mirroring the best components of the former Optigenex-Ceregenex relationship and expanding upon them to capitalize on the added depth and reach bHIP Global brings to network marketing venues worldwide.
AC-11® is a patented, all natural rain forest botanical extract developed by Optigenex that has been shown through clinical studies to work both topically and orally to help the body's natural ability to repair damaged DNA as a result of overexposure to the sun and other internal and external stressors.
As part of the acquisition from Ceregenex, bHIP Global assumes rights for the popular advanced dietary supplement called AIO Premium Cellular Health™ with AC-11® and will expand marketing of this product along with the equally popular Activar® brand line of next generation topical cosmeceuticals, also with AC-11®. The company expects to introduce new AC-11®-based products in the coming months.
Daniel Zwiren, president and CEO of Optigenex, said, "The joining of Ceregenex's excellent sales force with bHIP Global's equally talented, but much larger team represents the kind of synergy we at Optigenex are happy to see in the select community of companies that comprise our highly valued customer/partners. We are excited to welcome bHIP Global and its impressive management group to be a part of the evolving AC-11® story, and are pleased to know that the many highly professional former members of the Ceregenex sales organization, now working with bHIP Global, will continue to be with us also. We are confident that the bHIP Global team and the former Ceregenex team, now united, will significantly enhance our company's growth, both in the near term and down the road. The fast start we have seen in just the first few days underscores that confidence."
Terry LaCore, CEO of bHIP Global, added, "bHIP is very excited to have completed the negotiations with Optigenex and is looking forward to a long relationship building the brand of AC-11® together."
About Optigenex Inc.:
Optigenex Inc. is a technology-based developer of proprietary healthy-aging products for various wellness-related industries, including, beauty, dietary supplements and personal care products. AC-11® (formerly known as C-MED-100®) is the company's patented all-natural extract from the medicinal herb Uncaria tomentosa. From its origins in the Amazon Rain Forest, AC-11® delivers unique bioactive compounds of water soluble carboxy alkyl esters (CAEs™) that form the backbone of the company's revolutionary approach to DNA care and healthy aging. For more information about Optigenex please visit our website: www.optigenex.com.
About bHIP Global Inc.:
bHIP Global, Inc. is a world-wide direct seller of health and nutritional products. For more information about bHIP Global, please visit us on the web at www.bhipglobal.com
Safe Harbor Statement
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to treat, diagnose, cure or prevent any disease. This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company's current expectations and beliefs. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. The forward-looking statements set forth the company's beliefs as of the date of this release, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
